Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Carbogen-Amcis"

17 News Found

Carbogen Amcis completes Swissmedic inspection of its facility in Vionnaz, Switzerland
News | September 28, 2022

Carbogen Amcis completes Swissmedic inspection of its facility in Vionnaz, Switzerland

This inspection continues a series of successful inspections by Swissmedic in Vionnaz with the first inspection in 2015 followed by 2016, 2017 and 2020.


Dishman Carbogen Amcis Q3FY22 PAT at Rs. 35.38 crore
News | February 05, 2022

Dishman Carbogen Amcis Q3FY22 PAT at Rs. 35.38 crore

Dishman Carbogen Amcis has reported consolidated financial results for the period ended December 31, 2021


Carbogen Amcis AG signs co-investment agreement
Biotech | August 25, 2021

Carbogen Amcis AG signs co-investment agreement

The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound


Dishman Carbogen Amcis announces successful results for treatment for vitamin D deficiency
News | May 21, 2021

Dishman Carbogen Amcis announces successful results for treatment for vitamin D deficiency

Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.


Margins under pressure; domestic market growth to slow down: Nirmal Bang
News | January 06, 2022

Margins under pressure; domestic market growth to slow down: Nirmal Bang

A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies


NH TherAguix releases new batch for AGuIX
Biotech | October 29, 2021

NH TherAguix releases new batch for AGuIX

The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company


IPM growth led by Covid  driven products to taper off in Q2FY22: Nirmal Bang
News | October 06, 2021

IPM growth led by Covid driven products to taper off in Q2FY22: Nirmal Bang

In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report